The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients

Table 1

Comparison of the baseline demographic and clinical parameters among all study patients, initial responders (IR), the rest of the study patients (Non-IR), sustained responders (SR), and the rest of the study patients (Non-SR) after treatment of CERA.

Case number	All (𝑛=61)	IR (𝑛=16)	Non-IR (𝑛=45)	SR (𝑛=12)	Non-SR (𝑛=49)
Age (years)	69.05 ± 15.28	67.50 ± 17.31	69.60 ± 14.66	70.58 ± 10.82	68.67 ± 16.26
Male 𝑛 (%)	28 (46%)	8 (50%)	20 (44%)	8 (67%)	20 (41%)
HD duration (months)	81 (44.5–118.25)	82 (38–116)	81 (45–121.5)	83.5 (50.25–118.75)	81 (41.75–118.25)
BW (kg)	57.26 ± 11.19	58.35 ± 13.46	57.39 ± 10.51	55.55 ± 12.05	58.18 ± 11.02
DM 𝑛 (%)	28 (46%)	7 (44%)	21 (47%)	8 (67%)	20 (41%)
Hepatitis 𝑛 (%)	4 (7%)	0 (0%)	4 (9%)	1 (8%)	3 (6%)
Kt/V	1.64 ± 0.23	1.57 ± 0.28	1.66 ± 0.21	1.62 ± 0.22	1.64 ± 0.24
Clotting during HD 𝑛 (%)	9 (15%)	1 (7%)	8 (17%)	1 (8%)	8 (16%)
Iron supplement 𝑛 (%)	5 (8%)	2 (13%)	3 (7%)	1 (8%)	3 (6%)
ACEI/ARB 𝑛 (%)	30 (49%)	9 (56%)	21 (47%)	5 (42%)	25 (51%)
Statins 𝑛 (%)	18 (30%)	6 (38%)	12 (27%)	5 (42%)	13 (27%)

HD, hemodialysis; BW, body weight; ACEI/ARB, angiotensin-converting enzyme inhibitors/blockers of angiotensin II receptor, type I.